Online first
Research paper (original)
Published online: 2025-02-05
Coordinated medical care program for neurofibromatosis type 1 children and youth in Poland influences the future of their affected parents as well — a single academic reference center experience and national program description
Abstract
Introduction. Neurofibromatosis type 1 (NF-1) is an inherited neoplastic syndrome. In Poland, most affected adults are unaware of the disease-related risk of cancer.
Material and methods. During 36 months of described pilotage, 764 children and youth, and 48.2% of familial cases, were registered.
Results. Among parents, 30.4% were unaware of NF-1 diagnosis and 10.8% had any knowledge of NF-1-related risk of malignancy. As a consequence of advised prophylactic examinations, in 6 (1.6%) parents, clinically silent tumors were detected accidentally in preclinical stage: one 1B-breast cancer, one IA malignant melanoma, 2 pheochromocytomas and 2 low-grade CNS gliomas.
Conclusions. The early successful prevention of malignancy in professionally counselled NF-1 patients, proven currently, necessitates the urgent extension of prophylaxis and coordinated medical care program to the whole NF-1 population, not only in Poland, but worldwide. Precise knowledge concerning the disease-related medical risks should become a subject of the training of medical professionals regardless of their specialty.
Keywords: neurofibromatosis type 1risk of malignancycoordinated medical care programadult
References
- Uusitalo E, Rantanen M, Kallionpää RA, et al. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol. 2016; 34(17): 1978–1986.
- Pasmant E, Vidaud M, Vidaud D, et al. Neurofibromatosis type 1: from genotype to phenotype. J Med Genet. 2012; 49(8): 483–489.
- Sabbagh A, Pasmant E, Imbard A, et al. NF1 molecular characterization and neurofibromatosis type I genotype-phenotype correlation: the French experience. Hum Mutat. 2013; 34(11): 1510–1518.
- Legius E, Messiaen L, Wolkenstein P, et al. International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021; 23(8): 1506–1513.
- Philpott C, Tovell H, Frayling IM, et al. The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics. 2017; 11(1): 13.
- Tao J, Sun D, Dong L, et al. Advancement in research and therapy of mutant malignant tumors. Cancer Cell Int. 2020; 20: 492.
- Landry JP, Schertz KL, Chiang YJ, et al. Comparison of Cancer Prevalence in Patients With Neurofibromatosis Type 1 at an Academic Cancer Center vs in the General Population From 1985 to 2020. JAMA Netw Open. 2021; 4(3): e210945.
- Well L, Döbel K, Kluwe L, et al. Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth. PLoS Genet. 2021; 17(5): e1009517.
- Online Mendelian Inheritance in Man: # 607785 JMML.
- Liy-Wong C, Mohammed J, Carleton A, et al. The relationship between neurofibromatosis type 1, juvenile xanthogranuloma, and malignancy: A retrospective case-control study. J Am Acad Dermatol. 2017; 76(6): 1084–1087.
- Bergqvist C, Hemery F, Jannic A, et al. Lymphoproliferative malignancies in patients with neurofibromatosis 1. Orphanet J Rare Dis. 2021; 16(1): 230.
- Alkhayyat M, Saleh MA, Coronado W, et al. Epidemiology of neuroendocrine tumors of the appendix in the USA: a population-based national study (2014-2019). Ann Gastroenterol. 2021; 34(5): 713–720.
- Uusitalo E, Kallionpää R, Kurki S, et al. Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer. 2016; 116(2): 211–217.
- Frayling I, Mautner VF, Minkelen Rv, et al. Breast cancer risk in neurofibromatosis type 1 is a function of the type of NF1 gene mutation: a new genotype-phenotype correlation. J Med Genet. 2018; 56(4): 209–219.
- Evans DG, Kallionpää RA, Clementi M, et al. Breast cancer in neurofibromatosis 1: survival and risk of contralateral breast cancer in a five country cohort study. Genet Med. 2020; 22(2): 398–406.
- Gensini F, Sestini R, De Luca A, et al. Early-onset malignant phyllodes breast tumor in a patient with germline pathogenic variants in NF1 and BRCA1 genes. Fam Cancer. 2021; 20(3): 195–199.
- Karwacki MW. Breast cancer risk (un)awareness among women suffering from neurofibromatosis type 1 in Poland. Contemp Oncol (Pozn). 2020; 24(2): 140–144.
- Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2): 327–332.
- Stewart DR, Korf BR, Nathanson KL, et al. Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018; 20(7): 671–682.
- Rozporządzenie Ministra Zdrowia z dnia 15 czerwca 2020 r. w sprawie programu pilotażowego w zakresie koordynowanej opieki medycznej nad chorymi z neurofibromatozami oraz pokrewnymi im rasopatiami. Dziennik Ustaw RP nr 2020.1185 [Journal of Laws of the Republic of Poland, Decree of Ministry of Health no. 2020.1185] 2020.
- Karwacki MW, Wysocki M, Perek-Polnik M, et al. Coordinated medical care for children with neurofibromatosis type 1 and related RASopathies in Poland. Arch Med Sci. 2021; 17(5): 1221–1231.
- Rutkowski P, Raciborska A, Szumera-Ciećkiewicz A, et al. Recommendations of the Polish Sarcoma Group on diagnostic-therapeutic procedures and control in patients with type 1 neurofibromatosis (NF1) and the associated malignant neoplasm of peripheral nerve sheaths. Nowotwory. Journal of Oncology. 2022; 72(2): 106–128.
- Zöller M, Rembeck B, Akesson HO, et al. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol. 1995; 75(2): 136–140.
- McGaughran JM, Harris DI, Donnai D, et al. A clinical study of type 1 neurofibromatosis in north west England. J Med Genet. 1999; 36(3): 197–203.
- Bergqvist C, Servy A, Valeyrie-Allanore L, et al. NF France Network. Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966. Orphanet J Rare Dis. 2020; 15(1): 37.
- Wilding A, Ingham SL, Lalloo F, et al. Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet. 2012; 49(4): 264–269.
- Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019; 30(5): 781–787.
- Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019; 144(8): 1941–1953.
- Jasiura A, Dera I, Szlachcic K, et al. Breast cancer screening programmes in selected European countries and Poland. Journal of Education, Health and Sport. 2021; 11(7): 11–21.
- Hu C, Hart SN, Gnanaolivu R, et al. A Population-Based Study of Genes Previously Implicated in Breast Cancer. N Engl J Med. 2021; 384(5): 440–451.